Newsfeeds - Spark Newswire

4 minute read

Amarin Highlights Publication Of REDUCE-IT Study Data Analysis On VASCEPA

Today, 7:56 PM

A new post hoc sub-analysis of the landmark REDUCE-IT Study, published in the Journal of the American Heart Association (JAHA), found VASCEPA® significantly reduced the risk of cardiovascular death, strokes, heart

AMRN

2 minute read

Earnings

Looking Into Amarin Corp’s Return On Capital Employed

By Benzinga Insights

Today, 7:56 PM

According to Benzinga Pro, during Q4, Amarin Corp (NASDAQ:AMRN) earned $14.70 million, a 211.76% increase from the preceding quarter. Amarin Corp also posted a total of $144.49 million in sales, a 1.73% increase since Q3.

AMRN

1 minute read

Lower Vascepa Volume Hits Amarin’s Q4 Topline Growth

By Vandana Singh

Today, 7:56 PM

Amarin Corp plc's (NASDAQ: AMRN)

AMRN

1 minute read

Amarin: Q4 Earnings Insights

By Benzinga Insights

Today, 7:56 PM

Amarin Corp (NASDAQ:AMRN) reported its Q4 earnings results on Tuesday, March 1, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

AMRN

1 minute read

Amarin Corp Q4 EPS $0.04 Beats $(0.02) Estimate, Sales $144.49M Beat $141.75M Estimate

By Bill Haddad

Today, 7:56 PM

Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.02) by 300 percent. This is a 300 percent increase over earnings of $0.01 per share from the same

AMRN

3 minute read

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight

By Shanthi Rexaline

Today, 7:56 PM

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.

ACAD